RESUMO
Mice BDF1 with L 1210 or mice BALB/c with plasmacytoma MOPS-406 after pretreatment with ineffective doses of 1-beta-D-ribofuranosyl-4-methylmercaptopyrazolo(3,4-d)pyramidin e (25 to 100 mg/kg per 5 days) were treated with 5-fluorouracil at the optimal dose 100 mg per day. This combination produced a 1.5-2-fold or 2 to 4 fold enhancement of the antitumour effect of 5-fluorouracil without simultaneous increase of lethal toxicity.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Animais , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Feminino , Fluoruracila/administração & dosagem , Leucemia L1210/tratamento farmacológico , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Transplante de Neoplasias , Plasmocitoma/tratamento farmacológico , Tionucleosídeos/administração & dosagemRESUMO
9 transplanted strains were used for the evaluation of antitumour effect of blastolysin. The short-term inhibition of the tumour growth was observed on the following models: breast cancer, stomach cancer, kidney cancer and chorionepithelioma.
Assuntos
Antibacterianos , Antibióticos Antineoplásicos/uso terapêutico , Neoplasias Experimentais/tratamento farmacológico , Animais , Avaliação Pré-Clínica de Medicamentos , Feminino , Glicopeptídeos/uso terapêutico , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Transplante de Neoplasias , Peptídeos/uso terapêutico , Extratos do Timo/uso terapêutico , Fatores de TempoRESUMO
Administration of ribamidyl (Rb) prior to Ara-C to intact mice or mice with implanted tumours enhanced Ara-C toxicity. The growth of tumours (plasmacytoma MOPC-21, adenocarcinoma of the small intestine (strain AKATON), mammary adenocarcinoma 755 (Ca 755) resistant to Ara-C or Rb was inhibited after coadministration of these drugs. The augmentation of toxic and antitumour effects of Ara-C by Rb is similar to the described effect of high doses of thymidine. This is in accordance with the enhancement of the intracellular pool of thymidine phosphates under the action of Rb. The toxicity of methotrexate in vivo was increased by coadministration with Rb. This effect may be connected with a decrease in purine precursors pool under the action of Rb.